Gilead Sciences has the data it’ll need to start transitioning patients taking Truvada for PrEP over to Descovy, a drug with a longer patient life. But once Truvada generics hit, it might be a ...
As expected, Gilead’s Descovy had no problem securing backing from an FDA panel of experts for HIV prevention in men and transgender women. But beyond that, it ran into some issues. On Wednesday, an ...
Descovy is not approved for preexposure prophylaxis (PrEP) in females because early studies did not test its effectiveness in preventing HIV from vaginal sex. Later research suggests it’s not more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results